Membranoproliferative glomerulonephritis future or investigational therapies: Difference between revisions
(Created page with "__NOTOC__ Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. {{Membranoproliferative glomerulonephritis...") |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
Todays treatment of Membranoproliferative Glomerulonephritis is going to focus on monoclonal antibodies such as Rituximab, which is one of the most effective treatment.<ref>{{Cite journal|last=Michael Rudnicki|first=|date=|title=Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies|url=|journal=BioMed Research International|volume=|pages=|via=}}</ref> | |||
{{Membranoproliferative glomerulonephritis}} | {{Membranoproliferative glomerulonephritis}} | ||
Line 8: | Line 9: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Nephrology]] | [[Category:Nephrology]] | ||
[[Category:Needs content]] | [[Category:Needs content]] |
Latest revision as of 18:25, 26 July 2018
Todays treatment of Membranoproliferative Glomerulonephritis is going to focus on monoclonal antibodies such as Rituximab, which is one of the most effective treatment.[1]
Membranoproliferative glomerulonephritis Microchapters |
Differentiating Membranoproliferative glomerulonephritis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Membranoproliferative glomerulonephritis future or investigational therapies On the Web |
American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis future or investigational therapies |
FDA on Membranoproliferative glomerulonephritis future or investigational therapies |
CDC on Membranoproliferative glomerulonephritis future or investigational therapies |
Membranoproliferative glomerulonephritis future or investigational therapies in the news |
Blogs on Membranoproliferative glomerulonephritis future or investigational therapies |
Directions to Hospitals Treating Membranoproliferative glomerulonephritis |
References
- ↑ Michael Rudnicki. "Rituximab for Treatment of Membranoproliferative Glomerulonephritis and C3 Glomerulopathies". BioMed Research International.